ArticleBritish journal of cancer2025

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors.

Daphne Day et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.